Why Preclinical Evidence Keeps Being Mistaken for Proof
A rat tendon is not a human tendon. The most common error in peptide discussion is treating an animal result as a human conclusion.
Most compounds in the peptide conversation sit at grade D in our evidence framework: animal and laboratory research, no meaningful human data. That is not a dismissal. Preclinical work is how every approved drug begins.
The problem is translation. Historically, only a minority of compounds that succeed in animal models go on to demonstrate benefit in human trials, and healing models are among the least predictive.
Three failure points
Dose. Animal dosing is expressed per kilogram in species with different metabolic rates and clearance. Converting those figures to a human schedule is an extrapolation, not a protocol.
Model. An induced, standardised injury in a young inbred rodent is not a middle-aged human tendon with years of loading history.
Publication. When a body of literature originates largely from one group of affiliated researchers, independent replication has not yet tested it — regardless of how many papers exist.
What honest reading looks like
Preclinical evidence justifies interest and further study. It does not justify a dose, a schedule, or a claim about outcomes in people.
This is why every compound page on this site separates evidence tiers rather than pooling them into a single verdict.
This article is educational and is not medical advice. It does not recommend or provide individualised dosing. Speak with a qualified healthcare professional about your own health.